Aspirin appears to mitigate NAFLD by decreasing lipid biosynthesis and inflammation, thereby promoting catabolic metabolism through the activation of PPARδ and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [87]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.